BPC-157 + TB-500 2mg (4mg total) 2mg

About This Compound

This blend combines BPC-157, a synthetic pentadecapeptide fragment based on a sequence identified in human gastric juice, with TB-500, a synthetic peptide corresponding to the N-terminal acetylated 17–23 fragment of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein originally isolated from the thymus. Each peptide carries an independent, decades-long research literature; Biopunk sources them combined into a single vial for researchers studying the two compounds alongside one another.

Research Context

On BPC-157: Sikiric et al. (2026, Pharmaceuticals) reviewed rodent research on BPC-157, documenting its examined relationship to endothelial integrity, microcirculation, and the nitric oxide system across hemorrhage and thrombosis models. Matek et al. (2026, Pharmaceuticals) reviewed preclinical rat studies of BPC-157 across tendon, ligament, and muscle injury models. Smoday et al. (2026, Pharmaceuticals) studied BPC-157 in a rat model of unilateral adrenalectomy, documenting changes in oxidative stress markers and NOS1-3/VEGF-A expression.

On TB-500 / thymosin beta-4: Goldstein and Kleinman (2015, Expert Opinion on Biological Therapy) reviewed the discovery and cellular pathways underlying Tβ4's documented activity across animal tissue research. Kleinman et al. (2023, International Immunopharmacology) reviewed Tβ4's examined relationship to fibrosis-associated pathways across multiple animal organ-fibrosis models, attributing much of the activity to its N-terminal fragment, Ac-SDKP. Renga et al. (2018, Expert Opinion on Biological Therapy) reviewed Tβ4's documented relationship to autophagy-linked inflammation pathways across various animal models.

Both component peptides appear on FDA's Category 2 bulk drug substance safety list, reflecting immunogenicity concerns and limited available human safety data.

Research Use Disclaimer

For Research Use Only. Not for human consumption.